Tru Niagen® Protocol

Cellular Mitochondrial Health

View protocol in-app

This protocol was developed for practitioners using Fullscript in the United States and the templates cannot be applied to accounts operating outside of the United States.

Tru Niagen® Pro 300

300 mg, once or twice per day, for a minimum 21 days (1)(2)(3)

Tru Niagen® Pro 500

500 mg, once or twice per day, for a minimum 21 days (1)(2)(3)

In healthy overweight adults, nicotinamide riboside in the form of nicotinamide riboside use was shown to significantly increase NAD+,1 an essential coenzyme involved in healthy mitochondria maintenance. Supplementation of nicotinamide riboside in healthy middle-aged and older adults also raised NAD+ levels. (3)

In animal models of premature aging, NAD+ levels were decreased, and NAD+ replenishment using nicotinamide riboside increased lifespan and healthspan through DNA repair and mitochondrial maintenance. (4)

Nicotinamide riboside treatment in sedentary older adults enhanced isometric strength in lower limbs and resulted in higher resistance to fatigue.5 A review of similar studies found nicotinamide riboside was most beneficial when combined with exercise training. (6)

Nicotinamide riboside supplementation augmented skeletal muscle NAD metabolome and suppressed levels of inflammatory cytokines in a placebo-controlled, double-blind, crossover trial of 70-80-year-old men. (7)

In four human subjects with heart failure, five to nine days of oral nicotinamide riboside supplementation increased mitochondrial respiration of peripheral blood mononuclear cells and inhibited proinflammatory cytokine gene expression. (8)

In preclinical rodent studies, supplementation with nicotinamide riboside suppressed noise-induced hearing loss, (9) increased the resistance to weight gain, (10) supported healthy blood glucose, reduced hepatic steatosis, and suppressed neuropathy in prediabetic mice fed a high-fat diet, (11) enhanced heart function in a model of genetic cardiomyopathy, (12) and delayed pathology and cognitive decline in mouse models of Alzheimer’s. (13)


The Fullscript Integrative Medical Advisory team has developed or collected these protocols from practitioners and supplier partners to help health care practitioners make decisions when building treatment plans. By adding this protocol to your Fullscript template library, you understand and accept that the recommendations in the protocol are for initial guidance and may not be appropriate for every patient.

View protocol in-app



Fullscript content philosophy

At Fullscript, we are committed to curating accurate, and reliable educational content for practitioners and patients alike. Our educational offerings cover a broad range of topics related to integrative medicine, such as supplement ingredients, diet, lifestyle, and health conditions.

Medically reviewed by expert practitioners and our internal Integrative Medical Advisory team, all Fullscript content adheres to the following guidelines:

  1. In order to provide unbiased and transparent education, information is based on a research review and obtained from trustworthy sources, such as peer-reviewed articles and government websites. All medical statements are linked to the original reference and all sources of information are disclosed within the article.
  2. Information about supplements is always based on ingredients. No specific products are mentioned or promoted within educational content.
  3. A strict policy against plagiarism is maintained; all our content is unique, curated by our team of writers and editors at Fullscript. Attribution to individual writers and editors is clearly stated in each article.
  4. Resources for patients are intended to be educational and do not replace the relationship between health practitioners and patients. In all content, we clearly recommend that readers refer back to their healthcare practitioners for all health-related questions.
  5. All content is updated on a regular basis to account for new research and industry trends, and the last update date is listed at the top of every article.
  6. Potential conflicts of interest are clearly disclosed.